Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2014-07-21 Regulatory Filings
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
FORM 8-A
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. The text describes the registration of Series A Junior Participating Preferred Stock Purchase Rights, including detailed terms of the rights, definitions, and conditions related to the rights plan. This is a regulatory filing related to securities registration and not a financial report, earnings release, or other specific report type. It does not contain financial statements or management discussion but is a formal regulatory filing to register securities. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-07-21 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, titled 'CURRENT REPORT' and dated July 18, 2014. It details amendments to the company's Restated Bylaws, specifically changes to Articles 2 and 4 regarding stockholder meeting procedures and nomination processes. The content focuses on governance changes rather than financial results, audit information, or other report types. Form 8-K is a current report used to announce significant corporate events, including changes in governance documents. The detailed description of bylaw amendments and procedural rules for stockholder nominations aligns with Board/Management Information filings, which cover announcements of changes in company governance or management structure. Therefore, the appropriate classification is MANG (Board/Management Information). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a proxy solicitation but a substantive governance update.
2014-07-21 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is reporting a press release about preliminary clinical results from a Phase I study, which is an event update rather than a financial report or detailed analysis. The document length is 2993 characters, which is relatively short and includes a press release as an exhibit. There is no detailed financial data or comprehensive report content. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2014-07-21 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02, which relates to "Results of Operations and Financial Condition," and states that the company issued a press release announcing second quarter financial results. It also mentions an upcoming investor conference call to discuss these results. The document includes a press release as an exhibit but does not contain detailed financial statements or comprehensive financial analysis itself. The length is 2903 characters, which is relatively short and consistent with a current report rather than a full financial report. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results and key highlights.
2014-07-21 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, titled 'CURRENT REPORT' and dated June 23, 2014. It reports the entry into a material definitive agreement, specifically an exclusive licensing agreement for drug development. The content focuses on the announcement of a significant contract and related financial terms, not on financial results or detailed financial statements. The document length is 3314 characters, which is relatively short and consistent with a current report announcing a material event. This matches the characteristics of a Regulatory Filing (RNS) rather than a full Annual Report, Earnings Release, or other detailed financial report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-06-27 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text specifically mentions the announcement of preliminary clinical results and a press release dated June 13, 2014. The document is relatively short (2962 characters) and primarily serves to file a press release as an exhibit. There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-06-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.